10 Best Medical Research Stocks to Buy According to Hedge Funds

4. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 92

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+, as determined by an FDA-authorized test, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, who have received one or two prior systemic treatment regimens. Management stated that KEYTRUDA and KEYTRUDA QLEX mark the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with PD-L1+ tumors.

The approvals were based on the Phase 3 KEYNOTE-B96 trial that showed the KEYTRUDA regimen lowered the risk of disease progression or death by 28%, and reduced the risk of death by 24% compared to placebo plus paclitaxel with or without bevacizumab.

Merck & Co., Inc. (NYSE:MRK) stated that KEYTRUDA QLEX’s effectiveness for its approved indications was supported by the adequate and well-controlled studies conducted with KEYTRUDA, along with additional data from MK-3475A-D77 comparing the pharmacokinetic, efficacy, and safety profiles of KEYTRUDA QLEX and KEYTRUDA.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people. Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.